Unity Biotechnology, Inc. - UBX Business Value to Revenue

Unity Biotechnology, Inc. (UBX) - corporate logo

Unity Biotechnology develops senolytics to combat cellular aging of the eyes, while the EV/Sales ratio on GURU.Markets captures market expectations, where the level indicates the parameter's status. Unique patents and venture capital ensure business stability as experienced management implements innovative therapy standards in neurology and ophthalmology.

UBX: Unity Biotechnology, Inc. Enterprise Value-to-Revenue Ratio 07/04/2022 - 11/19/2026

UBX (unitybiotechnology.com): analytical breakdowns and indicator data

- market value and analyst target forecast:
Fundamental company valuation:UBX Unity Biotechnology, Inc.
Flagship merchandise of Unity Biotechnology

The business scale and market value of Unity Biotechnology (UBX) are clearly reflected through the historical EV/Sales trend. This indicator compares the total enterprise value with revenue, excluding debt load, which allows for an assessment of how effectively innovations in treating age-related eye pathologies are capitalized, regardless of macroeconomic cycles or global GDP growth rates.

Direct competitors

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Enterprise Value-to-Revenue Ratio Bionano Genomics BNGO|Business Value to Revenue APDN|BLUE - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume IPA|Omega Therapeutics, Inc. (OMGA) - Enterprise Value-to-Revenue Ratio|Singular Genomics Corp (OMIC) - EV/Sales Multiple|RGLS (Regulus Therapeutics, Inc.) - EV/Sales Multiple|SYRS: Business Value to Revenue|Company Value to Revenue TBIO (Telesis Bio Inc.)|EV/Sales Multiple TRACON Pharmaceuticals Inc. (TCON)